The World Health Organization recommends swapping non-nucleoside reverse transcriptase inhibitors (NNRTI) regimens for a dolutegravir-based combination because of widening resistance to NNRTIs.1 To help guide this transition, this comparison of switch strategies in people with a viral load below or above 1000 copies was conducted in the VISEND study. Dr Nyuma Mbewe (University of Zambia, Lusaka, Zambia) joins touchINFECTIOUSDISEASES to discuss this study.
The presentation entitled ‘Incident tuberculosis as a risk factor for viral non-suppression 48 weeks among patients switched to dolutegravir based therapy with recycled nucleoside reverse transcriptase inhibitors in Lusaka, Zambia’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- What did the VISEND study teach us about the use of dolutegravir and recycled tenofovir and lamivudine in people with HIV?
- What were the aims, design, and findings of the current sub-analysis of the VISEND data?
- Based on this analysis, what are your recommendations for clinical practice and for further study?
Disclosures: Nyuma Mbewe has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
- Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO/CDS/HIV/19.15). Licence: CC BY-NC-SA 3.0 IGO.
Share this Video
Related Videos In Respiratory Infections
Chronic pulmonary aspergillosis, an update on diagnosis and treatment: David Denning, ECCMID 2023
Chronic pulmonary aspergillosis (CPA) is a complicated respiratory disease associated with high morbidity and mortality rates. This overlooked disease often comes with delayed diagnosis and treatment, demonstrating a need for increased awareness and education in this area. We met with Prof. David Denning (The University of Manchester, Manchester, United Kingdom) to discuss the current state […]
Timothy Rodwell, ICEID 2022: The advantages of next-generation sequencing in MDR-TB treatment
Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) talked to us about the advantages, efficacy and cost-effectiveness […]
Timothy Rodwell, ICEID 2022: Shedding light on new MDR-TB treatment decisions with next generation sequencing
Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) discusses the limitations of MDR-TB diagnosis and assessment as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!